The study plans the inclusion of 12 patients in 5 French clinical centers
The first results are expected in the 3rd quarter of 2024
This study makes it possible to evaluate the intravenous administration of phages, particularly suitable for addressing indications with very high medical issues.
Lyon (France) and Cambridge (MA, US), April 15, 2024 – 7:30 a.m. CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: FR0011471135), today announces the inclusion of the 1st patient from the phase 1 clinical trial in the Infective endocarditis caused by Staphylococcus aureus (S. aureus).
Prof. Pascal Lim, Head of Cardiac Intensive Care at Henri Mondor Hospital and principal investigator of the study, comments: “The treatment of infective endocarditis linked to S. aureus presents many challenges and we are delighted to participate in this study which will evaluate for the first time phage therapy in this pathology whose mortality remains high. We thus hope to contribute to improving the care of patients who often find themselves in a therapeutic impasse. »
If you wish to receive all of the company’s financial communications in real time, you can register directly by email to the following address: [email protected]